From Name:
From Email:
To Name:
To Email:

Optional Message:

Vemurafenib will open floodgates for melanoma genotyping

from Internal Medicine News

The genotyping era of melanoma management will start with genetic assessment of every patient with advanced-stage melanoma becoming the standard of care, as soon as the Food and Drug Administration approves marketing of vemurafenib, the small-molecule inhibitor of a mutated form of the BRAF gene. Results from genotyping studies of metastatic melanoma tumors have shown a BRAF mutation prevalence of about 43 percent and a NRAS mutation prevalence of about 14 percent, with the remaining 43 percent of tumors having wild type forms of both genes. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063